Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space.Oncology or cancer is one of the most sought-after areas in the pharma/biotech space....

PFE : 23.97 (+0.38%)
BMY : 46.86 (+0.04%)
Private-Sector Oncology May Be the Market’s Best-Understood Secret

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer drug prices are rising sharply, with Bloomberg reporting growing concern over affordability and...

ONCY : 0.6901 (-6.74%)
INCY : 68.46 (+0.28%)
QGEN : 46.76 (+0.45%)
ONC.TO : 0.96 (-1.03%)
BMY : 46.86 (+0.04%)
BNTX : 106.53 (+2.04%)
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on...

AZN : 69.95 (-1.14%)
MRK : 79.06 (-0.29%)
PFE : 23.97 (+0.38%)
BMY : 46.86 (+0.04%)
Stocks Slightly Higher as Bond Yields Decline

The S&P 500 Index ($SPX ) (SPY ) today is up +0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.10%. June E-mini S&P futures (ESM25...

$SPX : 5,967.84 (-0.22%)
JPM : 275.00 (+0.38%)
ADI : 228.35 (-0.57%)
MRK : 79.06 (-0.29%)
ORCL : 205.17 (-2.70%)
$IUXX : 21,626.39 (-0.43%)
NQU25 : 21,844.75s (-0.46%)
AMGN : 289.33 (-0.10%)
BMY : 46.86 (+0.04%)
QQQ : 526.83 (-0.41%)
ZNU25 : 110-315s (+0.17%)
ESU25 : 6,018.00s (-0.27%)
Stocks Tumble and Oil Surges on Middle East Jitters

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.84%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.00%. June E-mini...

UAL : 74.27 (-0.04%)
MPC : 169.12 (+1.02%)
DHI : 124.20 (+2.41%)
CVX : 149.55 (+0.92%)
MRK : 79.06 (-0.29%)
LVS : 41.68 (-0.24%)
$IUXX : 21,626.39 (-0.43%)
ALKS : 29.09 (-0.82%)
PFE : 23.97 (+0.38%)
ZNU25 : 110-315s (+0.17%)
OXY : 45.63 (+0.62%)
ESU25 : 6,018.00s (-0.27%)
2 Beaten-Down Dividend Stocks to Buy Right Now

TGT : 95.54 (+0.44%)
BMY : 46.86 (+0.04%)
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

Bristol Myers BMY is focused on developing drugs with presence in oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. BMY depends on label expansion of approved...

MRK : 79.06 (-0.29%)
AMGN : 289.33 (-0.10%)
BMY : 46.86 (+0.04%)
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024...

AZN : 69.95 (-1.14%)
MRK : 79.06 (-0.29%)
PFE : 23.97 (+0.38%)
BMY : 46.86 (+0.04%)
BMY Reports Positive Data on Sotyktu From Arthritis Study

Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint.Sotyktu is an oral, selective tyrosine kinase...

BAYRY : 7.6800 (-1.16%)
NVS : 115.77 (-0.16%)
BMY : 46.86 (+0.04%)
BNTX : 106.53 (+2.04%)
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.6901 (-6.74%)
ARVN : 7.44 (-0.40%)
NVS : 115.77 (-0.16%)
ONC.TO : 0.96 (-1.03%)
PFE : 23.97 (+0.38%)
BNTX : 106.53 (+2.04%)
BMY : 46.86 (+0.04%)

Barchart Exclusives

Why PayPal Stock Is a Screaming Buy for the Second Half of 2025
PayPal stock has fallen almost 20% for the year and now trades at attractive valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar